Trial Profile
An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Aug 2014
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Pfizer
- 15 Aug 2014 New trial record
- 04 Jan 2011
- 16 Mar 2009